Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis
Alexandre Sepriano(Hospital de Egas Moniz), Martín Rudwaleit(Bielefeld University), Irene van der Horst‐Bruinsma(Radboud University Nijmegen), Rafael Valle‐Oñate(Hospital Militar Central), Nurullah Akkoç(Izmir Institute of Technology), Yeşim Kirazlı(Ege University), James Cheng‐Chung Wei(China Medical University), Filip Van den Bosch(Ghent University Hospital), Ulrich Weber(Justus-Liebig-Universität Gießen), Ignazio Olivieri(Ospedale Madonna Delle Grazie), Eduardo Collantes‐Estévez(Hospital Universitario Reina Sofía), Helena Marzo‐Ortega(University of Leeds), Salih Özgöçmen(Tokat Gaziosmanpaşa Üniversitesi), Jürgen Braun(Center for HIV and Hepatogastroenterology), Walter P. Maksymowych(University of Alberta), Salvatore Scarpato, Oliver FitzGerald(University College Dublin), J. Brandt(German Rheumatism Research Centre), Joachim Sieper(Charité - Universitätsmedizin Berlin), Euthalia Roussou(Barking, Havering And Redbridge University Hospitals NHS Trust), Jieruo Gu(Sun Yat-sen University), Maxime Dougados(Inserm), Désirée van der Heijde(Leiden University Medical Center), Robert Landewé(Zuyderland Medisch Centrum), Inge Juul Sørensen(University of Copenhagen), Feng Huang(Chinese PLA General Hospital)
Cited by 66
Related Papers
What low back pain is and why we need to pay attention
|The Lancet|2018|4.7k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Prevention and treatment of low back pain: evidence, challenges, and promising directions
|The Lancet|2018|2.5k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k